Skip to Content

Herceptin Hylecta Approval History

FDA Approved: Yes (First approved February 28, 2019)
Brand name: Herceptin Hylecta
Generic name: trastuzumab and hyaluronidase-oysk
Dosage form: for Subcutaneous Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination of the approved HER2/neu receptor antagonist trastuzumab (Herceptin) and recombinant human hyaluronidase PH20 (an enzyme that helps to deliver trastuzumab under the skin) indicated for the treatment of HER2-overexpressing breast cancer.

Development History and FDA Approval Process for Herceptin Hylecta

DateArticle
Feb 28, 2019Approval FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide